InterMune To Discuss Pirfenidone With FDA

March 5, 2010 11:01 AM |
InterMune Inc. (Nasdaq: ITMN) will meet with the Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee to discuss the company's idiopathic pulmonary firbrosis treatment pirfenidone. Shares of the biotechnology company leaped $8.08 to $22.69.

 

Tags:

Search

About this Entry

This page contains a single entry by published on March 5, 2010 11:01 AM.

Same Store Sales Rise For Family Dollar Stores was the previous entry in this blog.

RCN To Go Private is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 5.12